XOMA Current Ratio 2006-2021 | XOMA

XOMA current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
XOMA Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.09B $0.01B 13.88
2021-03-31 $0.07B $0.01B 5.36
2020-12-31 $0.09B $0.01B 7.16
2020-09-30 $0.05B $0.01B 3.90
2020-06-30 $0.05B $0.01B 4.63
2020-03-31 $0.06B $0.01B 5.57
2019-12-31 $0.06B $0.01B 6.76
2019-09-30 $0.04B $0.01B 4.37
2019-06-30 $0.05B $0.01B 3.90
2019-03-31 $0.05B $0.01B 7.20
2018-12-31 $0.05B $0.01B 8.35
2018-09-30 $0.03B $0.01B 5.37
2018-06-30 $0.04B $0.00B 12.45
2018-03-31 $0.04B $0.01B 7.26
2017-12-31 $0.04B $0.01B 5.96
2017-09-30 $0.05B $0.01B 3.45
2017-06-30 $0.02B $0.02B 1.08
2017-03-31 $0.02B $0.02B 0.97
2016-12-31 $0.03B $0.03B 0.84
2016-09-30 $0.02B $0.02B 0.98
2016-06-30 $0.04B $0.02B 1.50
2016-03-31 $0.05B $0.02B 2.45
2015-12-31 $0.07B $0.02B 3.10
2015-09-30 $0.07B $0.06B 1.26
2015-06-30 $0.06B $0.03B 1.88
2015-03-31 $0.07B $0.03B 2.75
2014-12-31 $0.08B $0.04B 2.31
2014-09-30 $0.07B $0.04B 1.78
2014-06-30 $0.08B $0.04B 2.22
2014-03-31 $0.10B $0.02B 4.97
2013-12-31 $0.13B $0.03B 4.29
2013-09-30 $0.08B $0.02B 3.45
2013-06-30 $0.07B $0.02B 3.12
2013-03-31 $0.08B $0.02B 4.17
2012-12-31 $0.10B $0.02B 4.02
2012-09-30 $0.07B $0.02B 3.15
2012-06-30 $0.08B $0.02B 4.15
2012-03-31 $0.09B $0.02B 4.71
2011-12-31 $0.06B $0.02B 3.04
2011-09-30 $0.06B $0.02B 3.03
2011-06-30 $0.06B $0.02B 3.23
2011-03-31 $0.07B $0.02B 3.03
2010-12-31 $0.06B $0.04B 1.66
2010-09-30 $0.03B $0.02B 1.48
2010-06-30 $0.02B $0.02B 1.24
2010-03-31 $0.04B $0.02B 1.89
2009-12-31 $0.03B $0.02B 1.72
2009-09-30 $0.03B $0.03B 1.27
2009-06-30 $0.04B $0.07B 0.65
2009-03-31 $0.05B $0.08B 0.63
2008-12-31 $0.04B $0.03B 1.43
2008-09-30 $0.04B $0.03B 1.23
2008-06-30 $0.05B $0.03B 2.03
2008-03-31 $0.03B $0.02B 1.73
2007-12-31 $0.06B $0.02B 2.46
2007-09-30 $0.07B $0.02B 3.06
2007-06-30 $0.04B $0.02B 2.13
2007-03-31 $0.05B $0.02B 2.56
2006-12-31 $0.06B $0.02B 3.03
2006-09-30 $0.03B $0.02B 1.99
2006-06-30 $0.04B $0.02B 2.73
2006-03-31 $0.05B $0.01B 3.18
2005-12-31 $0.05B $0.02B 3.04
2005-09-30 $0.05B $0.01B 4.61
2005-06-30 $0.06B $0.01B 5.17
2005-03-31 $0.07B $0.02B 4.44
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.267B $0.029B
XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86